<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736240</url>
  </required_header>
  <id_info>
    <org_study_id>022152015003</org_study_id>
    <nct_id>NCT02736240</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)</brief_title>
  <official_title>Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Developed Cooperatively by YunNan Walvax Biotechnology Co., Lt and Yuxi Walvax Biotechnology Co., Lt Among 2-71 Months (the Youngest Could be 6 Weeks) Healthy Infants and Toddlers by Randomized Blind Method With Similar Control in Multi-centers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walvax Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walvax Biotechnology Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and valuate the immunogenicity and safety of the&#xD;
      13-valent pneumococcal polysaccharide conjugate vaccine in 2-71 months old healthy infants&#xD;
      and toddlers (the youngest could be 6 weeks old)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2016</start_date>
  <completion_date type="Actual">December 3, 2017</completion_date>
  <primary_completion_date type="Actual">December 3, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>positive rate after infant doses</measure>
    <time_frame>30 days after infant doses</time_frame>
    <description>the rate of the immunoglobulin G ≥0.35μg/ml after infant doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMC after infant doses</measure>
    <time_frame>30 days after infant doses</time_frame>
    <description>geometrical mean concentration of immunoglobulin G after infant doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>positive rate after booster dose</measure>
    <time_frame>30 days after booster dose</time_frame>
    <description>the rate of the immunoglobulin G ≥0.35μg/ml after booster dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMC after booster dose</measure>
    <time_frame>30 days after booster dose</time_frame>
    <description>geometrical mean concentration of immunoglobulin G after booster dose</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2760</enrollment>
  <condition>Diseases Caused by Streptococcus Pneumoniae Serotypes</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent pneumococcal conjugate vaccine</intervention_name>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal polysaccharide conjugate vaccine</intervention_name>
    <arm_group_label>Test Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  2-71 months (the youngest could be 6 weeks old) infants or toddlers which are&#xD;
             positively healthy based on the medical history, the physical examination and the&#xD;
             judgment of the investigator;&#xD;
&#xD;
          -  The statutory guardian (or the consignor) of the subject agree his/her child&#xD;
             participate in the study, and is willing to sign the informed consent form;&#xD;
&#xD;
          -  The subject and his/her statutory guardians (or the consignor) are able to comply with&#xD;
             the requests of the clinical study protocol;&#xD;
&#xD;
          -  Never be immunized with any pneumococcus vaccine, and didn't get immunization with any&#xD;
             other preventive product in the past 10 days (didn't get immunized with attenuated&#xD;
             live vaccine in the past 14 days);&#xD;
&#xD;
          -  The auxillary temperature ≤37℃.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has already been immunized with pneumococcus vaccine no matter it is experimental or&#xD;
             marketed;&#xD;
&#xD;
          -  With the history of invasive disease caused by streptococcus pneumonia by culture;&#xD;
&#xD;
          -  With the history of serious allergy to any vaccine or drug, has got fever higher than&#xD;
             39℃ related to immunization with preventive biological product;&#xD;
&#xD;
          -  Infant that the birth weight is lighter than 2.5 kg;&#xD;
&#xD;
          -  With the history or the family history of seizure, epilepsy, cerebropathy and&#xD;
             psychosis ;&#xD;
&#xD;
          -  Infant with the abnormal labor (difficult labor, deliver with apparatus) or with the&#xD;
             history of asphyxia or nervous damage;&#xD;
&#xD;
          -  With the history of thrombocytopenia or other coagulation disorders by definite&#xD;
             diagnosis;&#xD;
&#xD;
          -  Infant or toddler with pathological jaundice by diagnosis;&#xD;
&#xD;
          -  Be known with or suspected with immunological dysfunction, including immunosuppressive&#xD;
             therapy (radiotherapy, chemotherapy, corticosteroid hormone, antimetabolites,&#xD;
             cytotoxic drug), HIV infection etc. ;&#xD;
&#xD;
          -  Be known with serious congenital malformation or serious chronic disease; suffer from&#xD;
             congenital malformation or be diagnosed with serious chronic disease (eg. Down&#xD;
             syndrome, diabetes mellitus, sickle cell anemia or nervous disease, Guillain-Barre&#xD;
             syndrome);&#xD;
&#xD;
          -  Be known with or suspected with diseases including: disease of respiratory system,&#xD;
             acute infection or the active period of chronic disease, serious cardiovascular&#xD;
             disease, hepatic-nephrotic disease, malignant tumor, skin disease;&#xD;
&#xD;
          -  Has taken blood product or globulin (the hepatitis B immune globulin is allowed);&#xD;
&#xD;
          -  Be participating in other clinical trials;&#xD;
&#xD;
          -  Any other situation which is considered to influence the evaluation of the study by&#xD;
             investigators .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>71 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nianmin Shi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chaoyang disease control and prevention center</affiliation>
  </overall_official>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>October 11, 2020</last_update_submitted>
  <last_update_submitted_qc>October 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

